XML 11 R4.htm IDEA: XBRL DOCUMENT v3.26.1
Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2026
Jun. 30, 2025
Jun. 30, 2026
Jun. 30, 2025
Revenues [Abstract]        
Revenue $ 71,553 $ 58,879 $ 142,427 $ 111,322
Operating expenses        
Cost of revenue 20,165 17,999 38,873 34,978
Research and development 19,153 24,134 42,776 48,337
Sales and marketing 26,414 23,573 52,760 46,620
General and administrative 21,168 17,786 42,152 35,185
Amortization of intangible assets 423 423 842 842
Total operating expenses 87,323 83,915 177,403 165,962
Loss from operations (15,770) (25,036) (34,976) (54,640)
Interest and other income, net 2,256 2,391 4,336 5,070
Interest expense (2,694) (2,948) (5,583) (5,853)
Loss on revenue interest liability extinguishment (23,733) 0 (23,733) 0
Net loss (39,941) (25,593) (59,956) (55,423)
Add: Net loss (income) attributable to noncontrolling interest 153 (21) 135 (43)
Net loss attributable to Adaptive Biotechnologies Corporation $ (39,788) $ (25,614) $ (59,821) $ (55,466)
Net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders, basic $ (0.25) $ (0.17) $ (0.38) $ (0.37)
Net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders, diluted $ (0.25) $ (0.17) $ (0.38) $ (0.37)
Weighted-average shares used in computing net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders, basic 159,855,257 152,082,284 157,700,126 150,646,632
Weighted-average shares used in computing net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders, diluted 159,855,257 152,082,284 157,700,126 150,646,632